Research programme: Alzheimer's disease therapeutics - Neuro-HitechAlternative Names: 2,3,4-Trihydroxybenzophenone; 4-Amino 1,1'-azobenzene-3,4'-disulfonic acid sodium salt
Latest Information Update: 25 Feb 2014
At a glance
- Originator Neuro-Hitech
- Mechanism of Action Amyloid beta-protein inhibitors; Tau protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 25 Feb 2014 Discontinued - Preclinical for Alzheimer's disease in USA (unspecified route)
- 02 Nov 2006 Preclinical trials in Alzheimer's disease in USA (unspecified route)